Molecular sequelae of histone deacetylase inhibition in human malignant B cells
- PMID: 12531799
- DOI: 10.1182/blood-2002-11-3514
Molecular sequelae of histone deacetylase inhibition in human malignant B cells
Abstract
Histone acetylation modulates gene expression, cellular differentiation, and survival and is regulated by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDAC inhibition results in accumulation of acetylated nucleosomal histones and induces differentiation and/or apoptosis in transformed cells. In this study, we characterized the effect of suberoylanilide hydroxamic acid (SAHA), the prototype of a series of hydroxamic acid-based HDAC inhibitors, in cell lines and patient cells from B-cell malignancies, including multiple myeloma (MM) and related disorders. SAHA induced apoptosis in all tumor cells tested, with increased p21 and p53 protein levels and dephosphorylation of Rb. We also detected cleavage of Bid, suggesting a role for Bcl-2 family members in regulation of SAHA-induced cell death. Transfection of Bcl-2 cDNA into MM.1S cells completely abrogated SAHA-induced apoptosis, confirming its protective role. SAHA did not induce cleavage of caspase-8, -9, or -3 in MM.1S cells during the early phase of apoptosis, and the pan-caspase inhibitor ZVAD-FMK did not protect against SAHA. Conversely, poly(ADP)ribose polymerase (PARP) was cleaved in a pattern indicative of calpain activation, and the calpain inhibitor calpeptin abrogated SAHA-induced cell death. Importantly, SAHA sensitized MM.1S cells to death receptor-mediated apoptosis and inhibited the secretion of interleukin 6 (IL-6) induced in bone marrow stromal cells (BMSCs) by binding of MM cells, suggesting that it can overcome cell adhesion-mediated drug resistance. Our studies delineate the mechanisms whereby HDAC inhibitors mediate anti-MM activity and overcome drug resistance in the BM milieu and provide the framework for clinical evaluation of SAHA, which is bioavailable, well tolerated, and bioactive after oral administration, to improve patient outcome.
Similar articles
-
Novel histone deacetylase inhibitors in the treatment of thyroid cancer.Clin Cancer Res. 2005 May 15;11(10):3958-65. doi: 10.1158/1078-0432.CCR-03-0776. Clin Cancer Res. 2005. PMID: 15897598
-
Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.Mol Cancer Ther. 2007 Nov;6(11):2967-75. doi: 10.1158/1535-7163.MCT-04-0344. Mol Cancer Ther. 2007. PMID: 18025281
-
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y. Breast Cancer Res. 2015. PMID: 25888415 Free PMC article.
-
Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.Int J Biochem Cell Biol. 2009 Apr;41(4):736-9. doi: 10.1016/j.biocel.2008.05.026. Epub 2008 Aug 3. Int J Biochem Cell Biol. 2009. PMID: 18725319 Review.
-
Histone deacetylase inhibitors: Potential in cancer therapy.J Cell Biochem. 2009 Jul 1;107(4):600-8. doi: 10.1002/jcb.22185. J Cell Biochem. 2009. PMID: 19459166 Free PMC article. Review.
Cited by
-
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.Leukemia. 2014 Mar;28(3):680-9. doi: 10.1038/leu.2013.231. Epub 2013 Aug 5. Leukemia. 2014. PMID: 23913134 Free PMC article.
-
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5. doi: 10.1073/pnas.2536759100. Epub 2003 Dec 26. Proc Natl Acad Sci U S A. 2004. PMID: 14695887 Free PMC article.
-
Targeted therapies in multiple myeloma.Target Oncol. 2009 Jan;4(1):23-36. doi: 10.1007/s11523-008-0102-9. Epub 2009 Jan 17. Target Oncol. 2009. PMID: 19343299 Review.
-
Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.Cancer Sci. 2013 Nov;104(11):1468-75. doi: 10.1111/cas.12271. Epub 2013 Oct 1. Cancer Sci. 2013. PMID: 23992541 Free PMC article.
-
Novel agents and new therapeutic approaches for treatment of multiple myeloma.World J Methodol. 2014 Jun 26;4(2):73-90. doi: 10.5662/wjm.v4.i2.73. eCollection 2014 Jun 26. World J Methodol. 2014. PMID: 25332907 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous